by TractManager | Jun 22, 2022 | Precision Medicine Insights
This report reviews the use of genetic testing for fibrous dysplasia/McCune-Albright syndrome.If you have a Hayes login, click here to view the full report on the Knowledge Center.
by TractManager | Jun 22, 2022 | Molecular Test Assessment
This report evaluates the analytical validity, clinical validity, and clinical utility of the clonoSEQ test (Adaptive Biotechnologies) specific to U.S. Food and Drug Administration (FDA)-cleared intended use.If you have a Hayes login, click here to view the full...
by TractManager | Jun 21, 2022 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of MiVu Mucosal Integrity Testing System (Diversatek Inc.) as an adjunct to clinical endoscopy for the diagnosis of...
by TractManager | Jun 17, 2022 | News
Clovis Oncology Inc. has announced a voluntary market withdrawal of Rubraca (rucaparib) in the U.S. as treatment of BRCA-mutated ovarian cancer after 2 or more chemotherapies. This withdrawal became effective on June 10, 2022, and does not affect other indications for...
by TractManager | Jun 17, 2022 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of aducanumab (Aduhelm; Biogen Inc.) for the treatment of patients with early-stage Alzheimer disease and mild...
Recent Comments